0812 GMT - RELX's performance update is reassuring, Baader analyst Alexandre Desprez writes in a research note. The reduction in federal funding for research seems to have no visible impact on the group, the analyst notes. The information-and-analytics company reported strong growth in article submissions at its scientific, technical and medical division. This will likely alleviate investors' concerns about the group's research segment, Desprez says. Shares are up 0.5% at 3,963 pence. (najat.kantouar@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 04:12 ET (08:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.